Global Icotinib Hydrochloride Tablets Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Icotinib Hydrochloride Tablets Market Research Report 2024
Icotinib (trade name Conmana) is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations.
According to Mr Accuracy reports new survey, global Icotinib Hydrochloride Tablets market is projected to reach US$ 28 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 8.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Icotinib Hydrochloride Tablets market research.
The Icotinib market is primarily driven by the demand for targeted therapies in the treatment of non-small cell lung cancer (NSCLC). Icotinib is a medication used as a tyrosine kinase inhibitor for patients with advanced NSCLC that carries EGFR mutations. The increasing prevalence of lung cancer, particularly among non-smokers and those with specific genetic mutations, contributes to market growth. Moreover, advancements in personalized medicine and the demonstrated efficacy of Icotinib in improving progression-free survival further propel adoption. However, challenges include managing the cost of targeted therapies and addressing potential drug resistance or adverse effects. Navigating patient access issues, optimizing treatment sequencing, and ensuring long-term safety are ongoing concerns. The market's success relies on continuous research in lung cancer treatment, collaborations between pharmaceutical manufacturers and oncologists, and comprehensive patient education on the benefits and potential risks of Icotinib treatment while addressing the evolving challenges associated with precision oncology and cancer treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Icotinib Hydrochloride Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bette Pharma
Segment by Type
250mg
125mg
Hospital
Drugs Store
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Icotinib Hydrochloride Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Icotinib Hydrochloride Tablets market is projected to reach US$ 28 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 8.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Icotinib Hydrochloride Tablets market research.
The Icotinib market is primarily driven by the demand for targeted therapies in the treatment of non-small cell lung cancer (NSCLC). Icotinib is a medication used as a tyrosine kinase inhibitor for patients with advanced NSCLC that carries EGFR mutations. The increasing prevalence of lung cancer, particularly among non-smokers and those with specific genetic mutations, contributes to market growth. Moreover, advancements in personalized medicine and the demonstrated efficacy of Icotinib in improving progression-free survival further propel adoption. However, challenges include managing the cost of targeted therapies and addressing potential drug resistance or adverse effects. Navigating patient access issues, optimizing treatment sequencing, and ensuring long-term safety are ongoing concerns. The market's success relies on continuous research in lung cancer treatment, collaborations between pharmaceutical manufacturers and oncologists, and comprehensive patient education on the benefits and potential risks of Icotinib treatment while addressing the evolving challenges associated with precision oncology and cancer treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Icotinib Hydrochloride Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bette Pharma
Segment by Type
250mg
125mg
Segment by Application
Hospital
Drugs Store
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Icotinib Hydrochloride Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices